Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025MedScienOpen Access

Research on Treatment Strategies for the Treatment of Sicklemia Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXinhong ZHANG

Discussion

Loading...

Member takes

Overview

Systematic review highlights gene editing advancements and hydroxyurea limitations for sickle cell disease.

Key Points

  • Clinical treatment for sickle cell disease shows limitations in long-term efficacy with current therapies, and emphasizes the need for advancements.
  • Gene editing with the CRISPR/Cas9 system demonstrates promise in correcting mutations and inducing fetal hemoglobin in human cell models.
  • Current therapeutic strategies include hydroxyurea, but possibilities such as hematopoietic stem cell optimization remain critical.
  • Challenges exist in gene editing safety and delivery, necessitating further exploration of novel methods and technologies for effective treatment.

Cite This Study

Xinhong ZHANG (2025) studied this question.

synapsesocial.com/papers/68af7c8d7567bf4f94ff3e9ehttps://doi.org/10.61173/1n9g9g06
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approaches2025 · 14 citations
  2. 2Sickle Cell Disease: From Ancient Origins to Modern Breakthroughs in Gene Therapy2026
  3. 3Hematopoietic stem cell therapy with gene modification to treat sickle cell disease2025 · 3 citations
  4. 4The CRISPR-Cas9 Technology Used for the Treatment of Single-Gene Genetic Diseases2025
  5. 5The Sickle Cell-Malaria Connection and the Promise of CRISPR Technology2024